Keywords: AAWS; CRPC; Enzalutamide; Enzalutamide withdrawal; Hormone therapy;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CRPC; aggressive variant; neuroendocrine; epigenetics; therapy; EZH2;
Keywords: prostatic neoplasms; prostate-specific antigen; neoplasm recurrence; local; prostatectomy; prognosis; ACM; all cause mortality; BCR; biochemical recurrence; CRPC; castration resistant prostate cancer; ePSADT; early PSADT; PCSM; prostate cancer specific mo
Keywords: Cancer; Metabolic syndrome; Drug-induced metabolic syndrome; MS; metabolic syndrome; IDF; International Diabetes Federation; ESH-ESC; The European Society of Cardiology and the European Society for Hypertension; IL-6, IL-10, IL-18; interleukins 6, 10 and
Keywords: PCa; prostate cancer; CRPC; castration-resistant prostate cancer; NED; neuroendocrine differentiation; NE; neuroendocrine; CgA; chromogranin A; NSE; neuron specific enolase; TMA; tissue microarray; DNPC; double-negative prostate cancer; AR; androgen recep
Keywords: Castrate-resistant prostate cancer; CRPC; Androgen deprivation therapy; ADT; LHRH; Immune therapy; Skeletal-related event (SRE);
Keywords: Abiraterone; Cardiac toxicity; CRPC; Enzalutamide; HSPC;
Keywords: prostatic neoplasms; castration-resistant; subcutaneous fat; prognosis; tomography; x-ray computed; mortality; ADT; androgen deprivation therapy; ARAT; androgen receptor axis targeted; BMI; body mass index; CCI; Charlson Comorbidity Index; CRPC; castratio
Keywords: ARSIs; androgen receptor signaling inhibitors; AA; abiraterone acetate; AR; androgen receptor; BPH; benign prostatic hyperplasia; CNV; copy number variation; CRPC; castration resistant prostate cancer; CTC; circulating tumor cells; ctDNA; cell-free circul
Keywords: ADT; androgen deprivation therapy; AE; adverse event; CRPC; castration-resistant prostate cancer; LHRH; luteinizing hormone-releasing hormone; mCRPC; metastatic CRPC; MFS; metastase-free survival; nmCRPC; non-metastatic CRPC; PFS; progression-free surviva
Keywords: PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: MS; mass-spectrometry; NMR; nuclear magnetic resonance spectroscopy; MRS; magnetic resonance spectroscopy; D-2-HG; D-2-hydroxyglutarate; α-KG; α-ketoglutarate; OAA; oxaloacetic acid; TET; ten-eleven translocation; GSH; glutathione; ROS; reactive oxygen
Keywords: Abiraterone; Circulating cell-free DNA; CRPC; Enzalutamide; Resistance;
Keywords: Androgens; Intracrinology; Steroid biosynthesis; Hormone-dependent cancer; Testosterone; 11-oxygenated androgens; 11KA4; 11-keto-androstenedione; 11KDHT; 11-keto-5α-dihydrotestosterone; 11KT; 11-keto-testosterone; 11OHA4; 11β-hydroxy-androstenedione; 11
Keywords: AR; androgen receptor; ARPI; androgen receptor pathway inhibition; CRPC; castrate-resistant prostate cancer; PCa; prostate cancer; BPH; benign prostate hyperplasia; ERα; estrogen receptor-α; PR; progesterone receptor; PRA; PR isoform A; PRB; PRB isoform
Keywords: ADT; Androgen deprivation therapy; AR; Androgen receptor; CRPC; Castration resistant prostate cancer; DHT; Dihydrotestosterone; EGF; Epidermal growth factor; EMT; Epithelial mesenchymal transition; ERβ; Estrogen receptor β; FGF; Fibroblast growth factor
Keywords: Sorafenib; Enzalutamide; Castration-resistant prostate cancer; Androgen receptor; Tyrosine kinase; PCa; prostate cancer; CRPC; castration-resistant prostate cancer; ADT; androgen deprivation therapy; AR; androgen receptor; Enz; enzalutamide; Sor; sorafeni
Keywords: AR; androgen receptor protein; BHK; baby hamster kidney; CMV IE; immediate early promoter of cytomegalovirus; CRPC; castration resistant prostate cancer; CYP17; 17α-hydroxy/17,20-lyase; DAPI; 4â²,6-diamidino-2-phenylindole; DBD; DNA-binding domain; DHT;
Keywords: LHRH; luteinizing hormone releasing hormone; ADT; androgen depletion therapy; CRPC; castration-resistant prostate cancer; CYP17; cytochrome P450 c17; MR; mineralocorticoid receptor; ER; estrogen receptor; PR; progestins receptor; GR; glucocorticoid recept
Keywords: prostatic neoplasms; immunotherapy; ADT; androgen deprivation therapy; APC; antigen presenting cell; CRPC; castration resistant prostate cancer; GM-CSF; granulocyte-macrophage colony-stimulating factor; mCRPC; metastatic castration resistant prostate canc
27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Keywords: 27-OHC; 27-hydroxycholesterol; ADT; androgen deprivation therapy; AR; androgen receptor; ATF4; Activating Transcription Factor 4; ATF6; Activating Transcription Factor 6; C/EBP; CCAAT / Enhancer binding proteins; CHOP; C/EBP homologous protein; CIP2A; can
Keywords: Adverse events; Age; CRPC; Neutrophil;
Keywords: prostatic neoplasms; castration-resistant; diabetes mellitus; metformin; docetaxel; mortality; ACG; Johns Hopkins Adjusted Clinical Groups; COX-2; cyclooxygenase-2; CRPC; castration resistant PCa; ICES; Institute for Clinical and Evaluative Sciences; mCRP
Keywords: prostatic neoplasms; neoplasm staging; practice guidelines as topic; guideline adherence; ADT; androgen deprivation therapy; APC; advanced prostate cancer; CRPC; castration resistant prostate cancer; EMR; electronic medical record; IUOGP; integrated urolo
Keywords: Prostate cancer; CRPC; Heterogeneity; BRCA; DRG; PARPi; PTEN;
Keywords: prostatic neoplasms; testosterone; prostate-specific antigen; leuprolide; mortality; ADT; androgen deprivation therapy; CAD; continuous androgen deprivation; CRPC; castration resistant prostate cancer; CSS; cause specific survival; IAD; intermittent andro
Keywords: ADT; androgen deprivation therapy; AR; androgen receptor; ASO; antisense oligonucleotide; CARN; castration-resistant Nkx3.1 expressing cells; CK; cytokeratin; CRPC; castration-resistant prostate cancer; DMBA; 7,12-dimethylbenz[a]anthracene; ECM; extracell
Keywords: Prostate cancer; Androgen receptor; AR-V7; Biomarker; CRPC;
Keywords: AA; accelerated approval; ALL; acute lymphoblastic leukemia; CCyR; complete cytogenetic response; CLL; chronic lymphocytic lymphoma; CML; chronic myeloid leukemia; CRC; colorectal carcinoma; CR; complete response; CRi; complete response with incomplete bl
Keywords: AA; abiraterone acetate; ADT; androgen deprivation therapy; AR; androgen receptor; AR-V; AR splice variant; CRPC; castration-resistant prostate cancer; CTC; circulating tumor cell; CYP; cytochrome P450; FDA; Food and Drug Administration; LBD; ligand-bindi
Keywords: prostatic neoplasms; castration-resistant; ADT; androgen deprivation therapy; AUA; American Urological Association; CRPC; castration resistant prostate cancer; FDA; Food and Drug Administration; mCRPC; metastatic castration resistant prostate cancer; PSA;
Keywords: ADT; CRPC; Metastasis; Prostate cancer; PSA
Keywords: ADT; androgen deprivation therapy; BALP; bone alkaline phosphatase; BMPs; bone morphogenetic proteins; BPs; bisphosphonates; CRPC; castration-resistant prostate cancer; ECM; extracellular matrix; ET-1; endothelin-1; ETAR; endothelin A receptor; ETBR; endo
Keywords: CRPC; Novel treatments; Abiraterone; Enzalutamide; Cabazitaxel; Sipuleucel T; Radium-223;
Keywords: Castration resistant prostate cancer; CRPC; Elderly; Abiraterone; Cabazitaxel; Sipuleucel-T; Enzalutamide; Alpharadin; Denosumab;
Keywords: APCI; atmospheric pressure chemical ionization; APPI; atmospheric pressure photochemical ionization; CDC; Center for Disease Control; CI; chemical ionization; CID; collision-induced dissociation; CRPC; castration-resistant prostate cancer; ELISA; enzyme-l
Keywords: ACTRIIB; activin receptor type-2B; APC; adenomatosis polyposis coli; APPR; acute phase protein response; ARC; arcuate nucleus; ATP; adenosine-5â²-triphosphate; C-26; colon-26 adenocarcinoma mouse model; CHO; Chinese hamster ovary; COPD; chronic obstructi
Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA
Keywords: cfDNA; ctDNA; Liquid biopsy; Castration-resistant; CRPC; Cell-free DNA;
Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan
Keywords: Abiraterone acetate; CRPC; Docetaxel; Enzalutamide; Oncological outcome;
miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1
Keywords: PCa; prostate cancer; CRPC; castration-resistant prostate cancer; miRNAs; microRNAs; EMT; epithelial-to-mesenchymal transition; snRNA; small nuclear RNA; PVDF; polyvinylidene difluoride; MiR-27b; miR-34a; Docetaxel sensitivity; ZEB1; EMT; Prostate cancer;
Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2
Keywords: CCL2; chemokine CC motif ligand 2; CRPC; castration-resistance prostate cancer; AR; androgen receptor; EMT; epithelial-to-mesenchymal transition; SPDEF; SAM pointed domain-containing ETS transcription factor; ADT; androgen-deprivation therapy; PTEN; phosp
eIF4E Phosphorylation in Prostate Cancer
Keywords: eIF4E; eukaryotic translation initiation factor 4E; mTOR; mammalian target of rapamycin; PCa; prostate cancer; Mnk; mitogen activated protein kinase interacting protein kinase; ADT; androgen deprivation therapy; MAPK; mitogen-activated protein kinase; CRP
Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation
Keywords: CRPC; castration-resistant prostate cancer; AR; androgen receptor; ADT; androgen deprivation therapy; RTK; receptor tyrosine kinase; COPA; cancer outlier profile analysis; OE; overexpressing; TUNEL; terminal deoxynucleotidyl transferase dUTP nick-end labe
Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer
Keywords: Andrographolide; Andrographis paniculata; Diterpene lactone; Anticancer; Chemotherapy; Bioactive lactone; ACS; American Chemical Society; AKT; activated protein kinase; Andro; Andrographolide derivative or conjugate; AP-1; activator protein-1; Cdk; Cyclin
A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer
Keywords: CRPC; castration-resistant prostate cancer; PI3K; Phosphatidylinositol-4,5-bisphosphate 3 kinase; PTEN; Phosphatase and tensin homolog; mTOR; mammalian target of rapamycin; BrdU; bromodeoxy-uridine; FITC; Fluorescein isothiocyanate; Skp2; S phase kinase-a
In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells
Keywords: IL-6; Macrophages; CRPC; NK cell cytotoxicity; PD-L1; NKG2D;
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid
Keywords: Aldo-keto reductase 1C3; AKR1C3; 17β-HSD5; Prostate cancer (PCa); CRPC; Bioisosterism; Scaffold hopping; Inhibitors; X-ray crystallography;
PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Keywords: CRPC; castration-resistant prostate cancer; ADT; androgen deprivation therapy; PI3K; phosphoinositide 3-kinase; AR; androgen receptor; PTEN; phosphatase and tensin homologue deleted on chromosome 10; INPP4B; inositol polyphosphate 4-phosphatase type II; P
HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo
Keywords: PPI; polyphyllin I; CRPC; castration-resistant prostate cancer; EZH2; Zeste homolog 2; DNMT1; DNA methyltransferase 1; HOTAIR; HOX transcript antisense RNA; ADT; androgen deprivation therapy; NF-κB; nuclear factor-kappaB; lncRNA; Long non-coding RNA; DNM
Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer
Keywords: CIL-102 derivatives; CR PCa; Docetaxel-resistant cancer; Anti-microtubule agents; Selectivity; Androgen deprivation therapy; ADT; Androgen-independent; AI; Androgen receptor; AR; Androgen-sensitive; AS; Castration-Resistant Prostate Cancer; CRPC; dichloro